Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company that entered the public markets through a merger with Health Sciences Acquisitions Corporation 2, a healthcare-focused special purpose acquisition company sponsored by Health Sciences Acquisitions, in 2019. The company is developing therapies targeting the neonatal Fc receptor to treat a range of autoimmune diseases and operates within the biopharmaceutical sector. Immunovant filed an 8-K with the Securities and Exchange Commission on August 28, 2025, under accession number 0001764013-25-000132, disclosing a material corporate event. As an active de-SPAC company in the healthcare space, Immunovant is among the names SpacDesk monitors from transaction close through ongoing public-company life. Sign up at SpacDesk for full filing histories, sponsor records, and deep data on de-SPAC companies across every sector.